Aspects of Microparticle Utilization for Potentiation of Novel Vaccines: Promises and Risks
Identifieur interne : 001C28 ( Main/Exploration ); précédent : 001C27; suivant : 001C29Aspects of Microparticle Utilization for Potentiation of Novel Vaccines: Promises and Risks
Auteurs : P. Ilyinskii [États-Unis, Niger]Source :
- NATO Science for Peace and Security Series B: Physics and Biophysics [ 1874-6500 ]
Abstract
Many recombinant vaccines against novel (HIV, HCV) or ever-changing (influenza) infectious agents require the presence of adjuvants/delivery vehicles to induce strong immune responses. The necessity of their improvement led to the major effort towards development of vaccine delivery systems that are generally particulate (e.g., nano- and microparticles) and have comparable dimensions to the pathogens (viruses or bacteria). The mode of action of these adjuvants is not fully understood but implies the stimulation of the innate or antigen-specific immune responses, and/or the increase of antigen uptake or processing by antigen-presenting cells (APC). Moreover, enhancement of adjuvant activity through the use of micro- and nanoparticulate delivery systems often resulted from the synergistic effects producing immune responses stronger than those elicited by the adjuvant or delivery system alone. Among particulate adjuvants, biodegradable micro- and nanoparticles of poly(D,L-lactide-co-glycoside) (PLGA) or poly(D,L-lactide) (PLA) have been reported to enhance both humoral and cellular immune responses against an encapsulated protein antigen. Cationic and anionic polylactide co-glycolide (PLG) microparticles have been successfully used to adsorb a variety of agents, which include plasmid DNA, recombinant proteins and adjuvant active oligonucleotides and are also currently tested in several vaccine applications. Another approach envisions specific targeting of APC, especially peripheral DC and exploitation of particulate systems that are small enough for lymphatic uptake (polystyrene nanobeads). Micro- and nanoparticles offer the possibility of enhancement of their uptake by appropriate cells through manipulation of their surface properties. Still, questions regarding toxicity and molecular interaction between micro- and nano-particles and immune cells, tissues and whole organisms remain to be addressed. These risks and other possible side effects should be assessed in detail especially if mass-production and massive administration of such preparations is to be considered.
Url:
DOI: 10.1007/978-90-481-2523-4_26
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 000228
- to stream Istex, to step Curation: 000228
- to stream Istex, to step Checkpoint: 000A34
- to stream Main, to step Merge: 001C30
- to stream Main, to step Curation: 001C28
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Aspects of Microparticle Utilization for Potentiation of Novel Vaccines: Promises and Risks</title><author><name sortKey="Ilyinskii, P" sort="Ilyinskii, P" uniqKey="Ilyinskii P" first="P." last="Ilyinskii">P. Ilyinskii</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:8BB7A57A20707B546F1D15158FE8EA99498C2FD3</idno><date when="2009" year="2009">2009</date><idno type="doi">10.1007/978-90-481-2523-4_26</idno><idno type="url">https://api.istex.fr/ark:/67375/HCB-HSKVCD1J-H/fulltext.pdf</idno><idno type="wicri:Area/Istex/Corpus">000228</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000228</idno><idno type="wicri:Area/Istex/Curation">000228</idno><idno type="wicri:Area/Istex/Checkpoint">000A34</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">000A34</idno><idno type="wicri:doubleKey">1874-6500:2009:Ilyinskii P:aspects:of:microparticle</idno><idno type="wicri:Area/Main/Merge">001C30</idno><idno type="wicri:Area/Main/Curation">001C28</idno><idno type="wicri:Area/Main/Exploration">001C28</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Aspects of Microparticle Utilization for Potentiation of Novel Vaccines: Promises and Risks</title><author><name sortKey="Ilyinskii, P" sort="Ilyinskii, P" uniqKey="Ilyinskii P" first="P." last="Ilyinskii">P. Ilyinskii</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Cure Lab, Inc., Bolivar Str., 216, 02021, Canton, MA</wicri:regionArea><placeName><region type="state">Massachusetts</region></placeName></affiliation><affiliation wicri:level="1"><country wicri:rule="url">Niger</country></affiliation></author></analytic><monogr></monogr><series><title level="s" type="main" xml:lang="en">NATO Science for Peace and Security Series B: Physics and Biophysics</title><idno type="ISSN">1874-6500</idno><idno type="ISSN">1874-6500</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">1874-6500</idno></seriesStmt></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Many recombinant vaccines against novel (HIV, HCV) or ever-changing (influenza) infectious agents require the presence of adjuvants/delivery vehicles to induce strong immune responses. The necessity of their improvement led to the major effort towards development of vaccine delivery systems that are generally particulate (e.g., nano- and microparticles) and have comparable dimensions to the pathogens (viruses or bacteria). The mode of action of these adjuvants is not fully understood but implies the stimulation of the innate or antigen-specific immune responses, and/or the increase of antigen uptake or processing by antigen-presenting cells (APC). Moreover, enhancement of adjuvant activity through the use of micro- and nanoparticulate delivery systems often resulted from the synergistic effects producing immune responses stronger than those elicited by the adjuvant or delivery system alone. Among particulate adjuvants, biodegradable micro- and nanoparticles of poly(D,L-lactide-co-glycoside) (PLGA) or poly(D,L-lactide) (PLA) have been reported to enhance both humoral and cellular immune responses against an encapsulated protein antigen. Cationic and anionic polylactide co-glycolide (PLG) microparticles have been successfully used to adsorb a variety of agents, which include plasmid DNA, recombinant proteins and adjuvant active oligonucleotides and are also currently tested in several vaccine applications. Another approach envisions specific targeting of APC, especially peripheral DC and exploitation of particulate systems that are small enough for lymphatic uptake (polystyrene nanobeads). Micro- and nanoparticles offer the possibility of enhancement of their uptake by appropriate cells through manipulation of their surface properties. Still, questions regarding toxicity and molecular interaction between micro- and nano-particles and immune cells, tissues and whole organisms remain to be addressed. These risks and other possible side effects should be assessed in detail especially if mass-production and massive administration of such preparations is to be considered.</div></front></TEI><affiliations><list><country><li>Niger</li><li>États-Unis</li></country><region><li>Massachusetts</li></region></list><tree><country name="États-Unis"><region name="Massachusetts"><name sortKey="Ilyinskii, P" sort="Ilyinskii, P" uniqKey="Ilyinskii P" first="P." last="Ilyinskii">P. Ilyinskii</name></region></country><country name="Niger"><noRegion><name sortKey="Ilyinskii, P" sort="Ilyinskii, P" uniqKey="Ilyinskii P" first="P." last="Ilyinskii">P. Ilyinskii</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/StressCovidV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001C28 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001C28 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= StressCovidV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:8BB7A57A20707B546F1D15158FE8EA99498C2FD3
|texte= Aspects of Microparticle Utilization for Potentiation of Novel Vaccines: Promises and Risks
}}
| This area was generated with Dilib version V0.6.33. |  |